Q3 tuli tässä viikolla, työkiireiden takia vähän viiveellä omat kommentit, kun ei muita aktiivisia kirjoittajia näköjään löydy 
Hyvää kasvua ja valuu nyt myös alariville asti kun kertakulut on käsitelty ja heikomman katteen toiminnot siirretty eteenpäin.
Physitrack Plc: Interim Report Q3 2026 – Growth Accelerating: Revenue Up 14 per cent, Two US Healthcare System Selections, EMR Launched, Company Profitable and Cash Generative
Third quarter: 1 July – 30 September 2026
Based on Alternative Key Performance Measures, the Company’s key financial highlights for the period are summarised below.
- Revenue increased 14 per cent to EUR 3.6m (EUR 3.2m), or 11 per cent at constant currency, the strongest growth of the year.
- Subscription revenue continued to represent the majority of Group revenue (94 per cent), reflecting the strength of the recurring SaaS model.
- Adjusted EBITDA decreased 8 per cent to EUR 1.1m (EUR 1.2m), corresponding to a margin of 31 per cent (38 per cent), reflecting deliberate investment in the North American commercial team and product launch activity.
- Adjusted EBITDA less CapEx decreased to EUR 0.3m (EUR 0.4m), with Group CapEx held at EUR 0.8m, in line with recent quarterly run rates, despite three product launches in the quarter.
- Operating cash flow from continuing operations amounted to EUR 1.1m (EUR 1.3m), with operating cash flow before adjusting items representing 106 per cent of adjusted EBITDA, marking the eighth consecutive quarter of positive operating cash flow.
- Free cash flow from continuing operations was positive at EUR 0.2m (EUR 0.5m). Net debt reduced to EUR 3.7m (30 June 2026: EUR 3.9m) and available liquidity was EUR 1.9m.
Jatkon osalta US-markkinan avaukset määrittää suunnan. Potentiaalia on tuplata liikevaihto EMR:n ja sen lisäpalveluiden kautta, varsinkin kun julkaistaan myös Australia, UK jne markkinoille.
Kannattavuus olisi sen jälkeen ihan eri luokkaa ja sitä kautta myös arvostus pitäisi aika pian ottaa loikkaa eteenpäin.
Redeyn kommentit ja Molinin haastattelu
https://www.redeye.se/research/1188215/physitrack-q3-interview-the-emr-has-become-a-global-play